Form 51-102F3
Material Change Report
MATERIAL CHANGE REPORT UNDER SECTION 7.1 OF NATIONAL INSTRUMENT
51-102
NOTE:
WHERE THIS REPORT IS FILED ON A CONFIDENTIAL BASIS PUT AT
THE BEGINNING OF THE REPORT IN BLOCK CAPITALS
“CONFIDENTIAL”.
Item 1.
Name and Address of Company
Vodis Pharmaceuticals Inc. (the “Company”)
8778 River Road,
Delta, BC,
V4G 1B4
Item 2.
Date of Material Change
October 18, 2016
Item 3.
News Release
The news release was disseminated through CSE, BC Securities Commission,
Ontario Securities Commission, Stockwatch and Market News.
Item 4.
Summary of Material Change
Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV) ("Vodis" or the
"Company") announces the completion of its Phase 2 expansion in their WA
facility in Bellingham.
Item 5.
Full Description of Material Change
Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV) ("Vodis" or the
"Company") announces the completion of its Phase 2 expansion in their WA
facility in Bellingham.
Vodis USA Inc., a fully owned subsidiary of Vodis Pharmaceuticals Inc., has
completed the build out of Phase Two expansion in its Bellingham facility. The
expansion consists of six more revenue generating rooms totaling 55% of the
allowed Tier 2 - 10,000sq/f production canopy capacity for its first tenant. The
entire production space has been outfitted with the latest lighting, air
conditioning, and production equipment, as well as the latest in WSLCB
compliant security equipment. The company’s tenant will be capable of
producing over 1,000,000 grams of dried Cannabis from this capacity expansion
per year.
The Company would also like to announce that Vodis USA Inc., has received the
municipal operating permits for Phase Two and has passed all of the applicable
Fire, Police, & Electric inspections. Operation of the space from the tenant will
commence pending inspection and approval by the Washington State Liquor and
Cannabis Board which is anticipated to take place in the next couple of weeks.
President & CEO Ivan Miliovski states “we are extremely pleased with the
completion of the Phase 2 expansion in our Bellingham facility and giving the
ability for our tenant to expand its production and capture a bigger market share,
while continuing to produce some of the highest quality of Cannabis products in
Washington State”.
About Vodis Pharmaceuticals Inc.
Vodis is one of North America’s foremost brand names in the medical and
recreational marijuana business with operations in both the United States and
Canada. Its master grow teams have consistently won or placed at each
competition they have entered with their “VIP” brand. The Company, with
facilities in BC and Washington State, is also actively looking into expansion
opportunities in other countries and states in the United States.
While Vodis Pharmaceuticals and its subsidiaries cannot have any interest
whatsoever in any proceeds as a result of production, processing or retail
activities in the United States, it can license its brand, production and consulting
services to approved Washington State license holders to ensure that all products
produced under the Vodis Pharmaceuticals program and/or associated under the
VIP brand meet or exceed the Vodis brand quality standards.
Item 6.
Reliance on Section 7.1(2) or (3) of National Instrument 51-102
Nothing in this form is required to be maintained on a confidential basis.
Item 7.
Omitted Information
Not applicable.
Item 8.
Senior Officers
Ivan Miliovski, CEO
Phone: (778) 242-9677
Item 9.
Date of Report
Dated at Vancouver this 18th day of October, 2016.
By: Vodis Pharmaceuticals Inc.
“Ivan Miliovski”
Ivan Miliovski, CEO